PL3920912T3 - Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) - Google Patents

Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)

Info

Publication number
PL3920912T3
PL3920912T3 PL20709049.9T PL20709049T PL3920912T3 PL 3920912 T3 PL3920912 T3 PL 3920912T3 PL 20709049 T PL20709049 T PL 20709049T PL 3920912 T3 PL3920912 T3 PL 3920912T3
Authority
PL
Poland
Prior art keywords
ciliopathies
gcs
inhibitors
treatment
glucosylceramide synthase
Prior art date
Application number
PL20709049.9T
Other languages
English (en)
Polish (pl)
Inventor
Oxana Ibraghimov-Beskrovnaya
Nikolay O. Bukanov
Hervé HUSSON
Sarah E. MORENO
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3920912T3 publication Critical patent/PL3920912T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20709049.9T 2019-02-04 2020-02-04 Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) PL3920912T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800993P 2019-02-04 2019-02-04
US201962851430P 2019-05-22 2019-05-22
PCT/US2020/016588 WO2020163337A1 (en) 2019-02-04 2020-02-04 Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)

Publications (1)

Publication Number Publication Date
PL3920912T3 true PL3920912T3 (pl) 2025-11-12

Family

ID=69740838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20709049.9T PL3920912T3 (pl) 2019-02-04 2020-02-04 Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)

Country Status (10)

Country Link
US (1) US12527776B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920912B1 (cg-RX-API-DMAC7.html)
JP (1) JP7633169B2 (cg-RX-API-DMAC7.html)
CN (1) CN114040762A (cg-RX-API-DMAC7.html)
AU (1) AU2020218185B2 (cg-RX-API-DMAC7.html)
ES (1) ES3040555T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072626T2 (cg-RX-API-DMAC7.html)
PL (1) PL3920912T3 (cg-RX-API-DMAC7.html)
PT (1) PT3920912T (cg-RX-API-DMAC7.html)
WO (1) WO2020163337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
WO2022169004A1 (ko) * 2021-02-05 2022-08-11 연세대학교 산학협력단 신규한 fabp4 억제제를 유효성분으로 포함하는 섬모형성 촉진용 조성물
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
CN115350278A (zh) * 2022-07-11 2022-11-18 清华大学 提高细胞内鞘脂类物质含量的试剂在制备纤毛异常相关疾病药物中的用途
CN120417900A (zh) 2022-12-01 2025-08-01 建新公司 文鲁司他与cyp3a4的强或中度抑制剂的组合
JPWO2025178019A1 (cg-RX-API-DMAC7.html) * 2024-02-19 2025-08-28
TW202606667A (zh) 2024-06-17 2026-02-16 美商健臻公司 使用葡萄糖神經醯胺合成酶抑制劑治療患有肝損傷之受試者的方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725228A (en) 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
BE640616A (cg-RX-API-DMAC7.html) 1962-12-19
NL130759C (cg-RX-API-DMAC7.html) 1965-10-07
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
ATE85217T1 (de) 1988-08-04 1993-02-15 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
IT1228293B (it) 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9106571D0 (en) 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
DE4326510A1 (de) 1993-08-06 1995-02-09 Bayer Ag Verfahren zur Herstellung von Cyclohexen-Derivaten
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
JP2000500139A (ja) 1995-11-08 2000-01-11 アメリカン・ホーム・プロダクツ・コーポレイション 1−アザビシクロヘプタン誘導体およびそれらの医薬用途
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EE9900034A (et) 1996-07-29 1999-08-16 Pharmacia & Upjohn Ab Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US5985836A (en) 1998-07-31 1999-11-16 Bayer Corporation Alpha-1 proteinase inhibitor binding peptides
CN1332726A (zh) 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
ATE247652T1 (de) 1999-03-29 2003-09-15 Neurogen Corp 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AU2001266100B9 (en) 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6896896B2 (en) 2000-07-19 2005-05-24 Unitika Ltd. Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
DE60216830T2 (de) 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
JP2003267977A (ja) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2393331T3 (es) 2002-07-17 2012-12-20 Actelion Pharmaceuticals Ltd. Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa
AU2003248122A1 (en) 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
ATE378048T1 (de) 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20050031683A1 (en) 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
TW200529860A (en) 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
JP2008504282A (ja) 2004-06-23 2008-02-14 ザ ファインスタイン インスティテュート フォー メディカル リサーチ コリンレセプターの薬理活性により腸閉塞を処置する方法
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
EP1891048A1 (en) 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
SG131819A1 (en) 2005-11-07 2007-05-28 Chikka Pte Ltd Buddy-based cross-carrier messaging system
JP2009523845A (ja) 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
US20090318491A1 (en) 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
US7840109B2 (en) 2006-08-14 2010-11-23 Adc Telecommunications, Inc. Factory spliced cable assembly
WO2008096870A1 (ja) 2007-02-09 2008-08-14 Astellas Pharma Inc. アザ架橋環化合物
CN101627014B (zh) 2007-03-09 2013-04-24 株式会社绿十字 用于预防或治疗帕金森病的(+)-3-羟基吗啡喃的口服可生物利用前药
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
EP2211856A4 (en) 2007-11-29 2011-02-09 Hospital For Sick Children COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2456438A2 (en) 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
ES2709487T3 (es) 2010-05-10 2019-04-16 Lesvi Laboratorios Sl Formulaciones farmacéuticas estables que contienen un antihistamínico
RU2436782C1 (ru) 2010-06-10 2011-12-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 2-МЕТОКСИ-4[(3aR,7aS)-3,3,6-ТРИМЕТИЛ-1,3,3a,4,5,7a-ГЕКСАГИДРО-2-БЕНЗОФУРАН-1-ИЛ]ФЕНОЛ - НОВОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TW201900625A (zh) 2013-03-15 2019-01-01 美商健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
EP3412296B1 (en) 2016-02-05 2025-11-12 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease
EP3452045A1 (en) 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US10588888B2 (en) * 2017-07-17 2020-03-17 Children's Hospital Medical Center CNS-accessible pharmacological chaperones for treatment of acid β-glucosidase-related disease states
US12472144B2 (en) 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
US10519157B2 (en) 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
SG11202107844UA (en) 2019-02-04 2021-08-30 Genzyme Corp Methods for treating symptoms and disorders associated with lysosomal storage diseases
ES3062389T3 (en) 2019-09-25 2026-04-10 Assia Chem Ind Ltd Solid state forms of lucerastat salts and process for preparation thereof
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
US20230372313A1 (en) 2020-07-30 2023-11-23 Genzyme Corporation Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same

Also Published As

Publication number Publication date
AU2020218185B2 (en) 2025-01-23
AU2020218185A1 (en) 2021-08-26
ES3040555T3 (en) 2025-11-03
PT3920912T (pt) 2025-09-09
EP3920912A1 (en) 2021-12-15
WO2020163337A1 (en) 2020-08-13
HUE072626T2 (hu) 2025-11-28
EP3920912B1 (en) 2025-06-11
CA3128043A1 (en) 2020-08-13
JP2022519131A (ja) 2022-03-18
CN114040762A (zh) 2022-02-11
JP7633169B2 (ja) 2025-02-19
US12527776B2 (en) 2026-01-20
US20220110922A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
HUE072626T2 (hu) Ciliopathiák kezelése glükozilceramid-szintáz (GCS) inhibitorok alkalmazásával
SMT202600187T1 (it) Ammine bicicliche come inibitori di cdk2
IL281939A (en) VAP-1 inhibitors
ZA202203770B (en) Pharmaceutical combination of prmt5 inhibitors
IL287767A (en) cdk inhibitors
IL256056A (en) Ezh2 inhibitors for treating lymphoma
IL291452A (en) Dosage forms for tyk2 inhibitors
EP3962484A4 (en) RAF KINASE INHIBITORS
IL257061A (en) Inhibitors of ezh2
IL285697A (en) Combined stress response pathway inhibitors
IL254266B (en) Glucosylceramide synthase inhibitors for the treatment of diseases
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
IL276145A (en) Triazolopyrimidine history for use as ghrelin O-acyltransferase inhibitors
IL281815A (en) Inhibitors of vap-1
IL288747A (en) Inhibitors of an integrated stress response pathway
IL279151A (en) Inhibitors of an integrated stress response pathway
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL254153A0 (en) Pharmaceutical compositions in salt form of semicarbazide-sensitive amine oxidase inhibitor (ssao)
GB201709136D0 (en) New therapeutic uses of enzyme inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
DK3188759T3 (da) Fremgangsmåde til behandling og sammensætninger, der omfatter en dobbelt pi3k-delta-gamma-kinaseinhibitor og et kortikosteroid
HK40070274A (en) Inhibitors of raf kinases
HK40033924A (en) Protein kinase c inhibitors for treatment of uveal melanoma
GB201618031D0 (en) New therapeutic uses of enzyme inhibitors
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors